HCPLive Network

Data Support Long-Term Efficacy for Opioid Therapy for Chronic Non-Cancer Pain

 
There are several ethical, regulatory, and logistical challenges to conducting long-term placebo-controlled, double-blind randomized controlled trials (RCTs). Because of this, the majority of contemporary phase III trials on opioid efficacy and safety do not last longer than three months.
 
In light of this, open-label studies are particularly valuable, as they are often of longer duration and “reflect patient experience before and after long-term opioid therapy,” according to the authors of a poster presented at the American Pain Society’s 32nd Annual Scientific Meeting, held May 8-13, 2013, in New Orleans, LA.
 
In “Long-term Efficacy and Safety of Opioid Therapy for Chronic Non-cancer Pain: Evidence from Randomized and Open-label Studies,” Matsuno, Wallace, Glanzman, et al, analyzed data from published RCTs and open-label studies that had a duration of six months or longer to learn more about the long-term efficacy and safety of opioid therapy for patients with chronic non-cancer pain.
 
They conducted a literature search of major databases to identify RCTs, single-arm open-label trials, and open-label extension studies following an RCT that were six months or more in duration. They also searched clinical guidelines, consensus statements, and other sources to identify additional articles.


Further Reading
Analysis of claims data finds patients often receive starting doses of Butrans that do not follow published recommendations, with more than one-third of patients receiving initial doses that are too low.
Results from a small study indicate patients with difficult-to-treat diabetic peripheral neuropathy (DPN) may benefit from therapy with tanezumab, a humanized monoclonal antibody against nerve growth factor.
Phase III study results show patients with chronic non-cancer pain and opioid-induced constipation (OIC) experienced improvements in spontaneous bowel movement frequency and other symptoms of OIC.
More Reading
$related2$
$AD300x250BB$